NANOVIRICIDES, INC. Restricted Stock or Unit Expense
NANOVIRICIDES, INC. (NNVC) reported Restricted Stock or Unit Expense of $29.83 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestrictedStockExpense · last filed 2019-05-15
- NANOVIRICIDES, INC. restricted stock or unit expense for the quarter ending 2019-03-31 was $29.83K.
- NANOVIRICIDES, INC. restricted stock or unit expense for the quarter ending 2018-12-31 was $6.36K.
- NANOVIRICIDES, INC. restricted stock or unit expense for the quarter ending 2018-09-30 was $7.77K.
| Period end | Restricted Stock or Unit Expense 3 month | Restricted Stock or Unit Expense 6 month | Restricted Stock or Unit Expense 9 month |
|---|---|---|---|
| 2019-03-31 | $29.83K 10-Q · filed 2019-05-15 | $36.19K derived: sum of 2 quarters · filed 2019-05-15 | $43.96K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $6.36K 10-Q · filed 2019-02-14 | $14.13K 10-Q · filed 2019-02-14 | |
| 2018-09-30 | $7.77K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |